We are live on ! Find out more

Cumberland Pharmaceuticals

CPIX

Market cap $65.2M

4.35 USD

-0.52

10.68%

At close Updated Oct 29, 4:00 PM EDT

Pre-market

After hours

4.36

+0.01

0.23%

1 day

-10.68%

5 days

-48.58%

1 month

-43.14%

3 months

-34.68%

6 months

3.33%

Year to date

9.3%

1 year

33.85%

5 years

61.71%

10 years

-8.42%

About: Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment, which is specialty pharmaceutical products. The company's target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The firm promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. Its brands include Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, and Vibativ. Geographically, the company generates revenue from China, South Korea, Russia, Mexico, Australia, and Saudi Arabia.

Employees: 93

Healthcare Drug Manufacturers - Specialty & Generic

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 9.1%

Neutral 72.7%

Negative 18.2%

Cumberland Pharmaceuticals Inc. (CPIX) Discusses Duchenne Cardiomyopathy NDA Submission and Product Development Strategy Prepared Remarks Transcript

Cumberland Pharmaceuticals Inc. (CPIX) Discusses Duchenne Cardiomyopathy NDA Submission and Product Development Strategy Prepared Remarks Transcript

Cumberland Pharmaceuticals Inc. (CPIX) Discusses Duchenne Cardiomyopathy NDA Submission and Product Development Strategy Prepared Remarks Transcript

Cumberland Pharmaceuticals Begins Rolling FDA NDA for Dyscorban in Duchenne Cardiomyopathy

Cumberland Pharmaceuticals NASDAQ: CPIX said it plans to begin a rolling New Drug Application submission for Dyscorban, its ifetroban candidate for cardiomyopathy associated with Duchenne muscular dystrophy, after the U.S. Food and Drug Administration granted the company's request for rolling review.

Cumberland Pharmaceuticals Begins Rolling FDA NDA for Dyscorban in Duchenne Cardiomyopathy

CUMBERLAND PHARMACEUTICALS ANNOUNCES PLANS TO FILE NEW DRUG APPLICATION FOR IFETROBAN DMD PROGRAM

NASHVILLE, Tenn., Oct. 26, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), ("Cumberland" or the "Company") an innovation-focused biopharmaceutical company developing new products for rare diseases, today provided an update on its ifetroban product candidate in development as a potential treatment for the cardiomyopathy associated with Duchenne muscular dystrophy ("DMD").

CUMBERLAND PHARMACEUTICALS ANNOUNCES PLANS TO FILE NEW DRUG APPLICATION FOR IFETROBAN DMD PROGRAM

Cumberland Pharmaceuticals Announces ASSIST-SSc Trial Top-Line Results

Ifetroban was well tolerated in patients with systemic sclerosis NASHVILLE, Tenn., Oct. 23, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), an innovation-driven biopharmaceutical company advancing new therapies that address significant unmet medical needs, announces top-line results from its Phase 2a ASSIST-SSc trial evaluating oral ifetroban for patients with systemic sclerosis ("SSc").

Cumberland Pharmaceuticals Announces ASSIST-SSc Trial Top-Line Results

CUMBERLAND PHARMACEUTICALS PROVIDES UPDATED WEBCAST REGISTRATION LINK FOR IFETROBAN DMD PROGRAM CALL

NASHVILLE, Tenn., Oct. 23, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation-driven biopharmaceutical company advancing new therapies that address significant unmet medical needs, confirmed that it will provide an update on its ifetroban product candidate in development as a potential treatment for the cardiomyopathy associated with Duchenne muscular dystrophy ("DMD").

CUMBERLAND PHARMACEUTICALS PROVIDES UPDATED WEBCAST REGISTRATION LINK FOR IFETROBAN DMD PROGRAM CALL

CUMBERLAND PHARMACEUTICALS ANNOUNCES NATIONAL CALL TO PRESENT AN UPDATE ON ITS IFETROBAN DMD PROGRAM

NASHVILLE, Tenn., Oct. 19, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation-driven biopharmaceutical company advancing new therapies that address significant unmet medical needs, announced today that it will provide an update on its ifetroban product candidate in development as a potential treatment for the cardiomyopathy associated with Duchenne muscular dystrophy ("DMD").

CUMBERLAND PHARMACEUTICALS ANNOUNCES NATIONAL CALL TO PRESENT AN UPDATE ON ITS IFETROBAN DMD PROGRAM

Cumberland Pharmaceuticals: Pivot Into Drug Development Creates Risk, Opportunity

Cumberland Pharmaceuticals Inc. has transformed from a commercial-stage pharma to a pre-revenue, Phase 2-stage biotech focused on rare diseases. Recent $100M asset sale to Apotex funds operations and pipeline, with a special dividend paid to shareholders and four late-stage clinical programs retained. All pipeline assets are based on ifetroban, targeting high-value indications like DMD cardiomyopathy, cancer metastasis, systemic sclerosis, and IPF.

Cumberland Pharmaceuticals: Pivot Into Drug Development Creates Risk, Opportunity

Cumberland Pharmaceuticals Inc. (CPIX) Q2 2026 Earnings Call Transcript

Cumberland Pharmaceuticals Inc. (CPIX) Q2 2026 Earnings Call Transcript

Cumberland Pharmaceuticals Inc. (CPIX) Q2 2026 Earnings Call Transcript

Cumberland Pharmaceuticals Q2 Earnings Call Highlights

Cumberland Pharmaceuticals NASDAQ: CPIX reported a second-quarter operating loss of $3.1 million as it prepared to transition from a commercial-stage specialty pharmaceutical company into an innovation-focused biopharmaceutical business following the sale of its branded U.S. commercial portfolio to Apotex Health.

Cumberland Pharmaceuticals Q2 Earnings Call Highlights

CUMBERLAND PHARMACEUTICALS REPORTS COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS

$100 million Strategic Transaction Closed Special Shareholder Dividend Funded Advancing Late Stage Clinical Pipeline NASHVILLE, Tenn., Aug. 4, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation-focused biopharmaceutical company, announced today its second quarter 2026 financial results and provided an update following the successful closing of its Strategic Transaction with Apotex Health.

CUMBERLAND PHARMACEUTICALS REPORTS COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS

See News Rankings

Price charts implemented using Lightweight Charts™